Pharnext SA
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of bac… Read more
Pharnext SA (PNEXF) - Total Liabilities
Latest total liabilities as of December 2023: $38.12 Million USD
Based on the latest financial reports, Pharnext SA (PNEXF) has total liabilities worth $38.12 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharnext SA - Total Liabilities Trend (2015–2023)
This chart illustrates how Pharnext SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharnext SA Competitors by Total Liabilities
The table below lists competitors of Pharnext SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NexOptic Technology Corp
PINK:NXOPF
|
USA | $2.25 Million |
|
NISOURCE (NOU.SG)
STU:NOU
|
Germany | €20.50 Billion |
|
Vatic Ventures Corp.
PINK:VCVVF
|
USA | $1.69 Million |
|
FIRSTENERGY - Dusseldorf Stock Exchang
DU:FE7
|
Germany | €37.06 Billion |
|
Ralliant Corporation Common Stock
NYSE:RAL
|
USA | $2.30 Billion |
|
AUBAY (BAQ.SG)
STU:BAQ
|
Germany | €196.21 Million |
|
Search Minerals Inc
PINK:SHCMF
|
USA | $6.92 Million |
Liability Composition Analysis (2015–2023)
This chart breaks down Pharnext SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharnext SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharnext SA (2015–2023)
The table below shows the annual total liabilities of Pharnext SA from 2015 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $38.12 Million | -6.96% |
| 2022-12-31 | $40.98 Million | +19.43% |
| 2021-12-31 | $34.31 Million | +1.59% |
| 2020-12-31 | $33.77 Million | +11.03% |
| 2019-12-31 | $30.42 Million | -46.96% |
| 2018-12-31 | $57.34 Million | +83.23% |
| 2017-12-31 | $31.30 Million | +65.26% |
| 2016-12-31 | $18.94 Million | -36.74% |
| 2015-12-31 | $29.93 Million | -- |